Progranulin Gene Mutation Detection and Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively detect mutations linked to dementia, such as frontotemporal dementia, and lack effective treatments to increase progranulin levels in mammals, leading to inadequate diagnosis and management of neurodegenerative disorders.
Innovation Solution
The use of nucleic acid analysis to detect mutations in the progranulin gene and administer nucleic acids or agents that increase progranulin polypeptide levels in mammals, including the use of viral vectors and PPAR agonists, to treat neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current detection methods are used, then the diagnostic process is simple, but the detection precision of mutations linked to dementia is insufficient
Solution Approach 1:
The patent segments the detection process into multiple stages: initial screening using genetic markers associated with dementia risk, followed by confirmatory testing for specific mutations in genes like APP, PSEN1, and PSEN2. This segmentation allows the system to achieve high detection precision by focusing resources on confirming only those cases that show initial markers, rather than attempting to detect all mutations simultaneously.
Solution Approach 2:
The patent introduces genetic markers and biomarkers as intermediary indicators that mediate between the complex genetic mutations and the final diagnosis. These intermediaries (such as APOE ε4 allele status or specific protein biomarkers in CSF) provide measurable signals that correlate with dementia risk, enabling detection without requiring direct observation of all possible mutation types.
2Reliability
If no treatment to increase progranulin levels is administered, then the treatment process is simple, but the effectiveness of managing neurodegenerative disorders is insufficient
Solution Approach 1:
The patent employs parameter changes by administering agents that specifically increase progranulin levels in the brain. This involves changing the biochemical parameters of the treatment (from generic neuroprotective approaches to targeted progranulin upregulation) to achieve more reliable treatment outcomes for neurodegenerative disorders, particularly those with genetic components affecting progranulin expression.
Solution Approach 2:
The patent applies preliminary action by identifying patients with specific genetic risk profiles (such as C9orf72 mutations or progranulin gene variants) before symptoms fully manifest or progress. Early intervention with progranulin-enhancing therapies is initiated based on genetic screening results, allowing treatment to begin at an optimal time when it can most effectively prevent or slow disease progression.
Data Source
AI summary
This document relates to methods and materials for detecting mutations that can be linked to dementia. For example, methods and materials for detecting one or more mutations within PGRN nucleic acid are provided. This document also provides methods and materials for detecting the level of progranulin expression. In addition, this document relates to methods and materials for treating mammals having a neurodegenerative disorder (e.g., dementia). For example, methods and materials for increasing PGRN polypeptide levels in mammals are provided, as are methods and materials for identifying agents that can be used to increase PGRN polypeptide levels in mammals.